Source item
Open original source ↗According to ARK’s research, multiomics will be the most profound application of #AI: helping to diagnose disease before any physical symptoms, slashing the cost and time to develop and deliver novel drugs, and curing disease…turning “sickcare” into healthcare! @Ovid_ARK
View ARKK holdings and information here. https://t.co/2mYbPxOzmX
2 segments
Segment 1 · characters 0–271 · Original segment ↗
Segment 2 · characters 273–337 · Original segment ↗
Quoted context
These are the quoted author’s words.
MULTIOMICS IS HAVING ITS BEST YEAR IN THE ARK INNOVATION ETF $ARKK Healthcare has historically underperformed in ARK’s exchange-traded funds (ETFs). But year to date, multiomics has been a positive contributor driven by strong data, new AI business models, and a return of mergers and acquisitions in biotech. Tempus, Twist, CRISPR, and Intellia all have meaningful near-term catalysts.
ARK_Funds ↗